💊 İlaçlar A-Z 🧬 Hedefler 🛠 Araçlar 📚 Rehberler
Tüm İlaçlar İlaç Sınıfları Terapötik Alanlar Yan Etkiler
Rehberler Sözlük Zaman Çizelgesi
Karşılaştırmalar İlaç Yolculukları İlaç Aileleri
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Colfosceril Palmitate

CHEMBL1200737 Phase 4 Onaylandı Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
734.0 g/mol
LogP
13.5
Phase
4

A synthetic surfactant used to treat respiratory distress syndrome in premature newborns whose lungs lack sufficient natural surfactant. It helps keep the tiny air sacs in the lungs open so the baby can breathe more easily.

Moleküler Ağırlık

734,0000 g/mol

LogP

13,50

TPSA

111,00 Ų

Lipinski RO5

Başarısız

Etki Mekanizması

Reduces surface tension at the air-liquid interface in the pulmonary alveoli, preventing alveolar collapse during expiration and improving lung compliance and gas exchange.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Reduces surface tension at the air-liquid interface in the pulmonary alveoli, preventing alveolar collapse during expiration and improving lung compliance and gas exchange.

2D Yapı

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC

                

                

                
                

                    
InChI

                    
InChI=1S/C40H80NO8P/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-39(42)46-36-38(37-48-50(44,45)47-35-34-41(3,4)5)49-40(43)33-31-29-27-25-23-21-19-17-15-13-11-9-7-2/h38H,6-37H2,1-5H3/t38-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C40H80NO8P

                    

                    
                    

                        
HBD / HBA

                        
- / 8

                    

                    
                    

                        
Döndürülebilir Bağlar

                        
40

                    

                    
                    
                    

                        
Ağır Atomlar

                        
50

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Sıkça Sorulan Sorular

                

                    
                    

                        
                        

                            
A synthetic surfactant used to treat respiratory distress syndrome in premature newborns whose lungs lack sufficient natural surfactant. It helps keep the tiny air sacs in the lungs open so the baby can breathe more easily.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Reduces surface tension at the air-liquid interface in the pulmonary alveoli, preventing alveolar collapse during expiration and improving lung compliance and gas exchange.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Colfosceril Palmitate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1200737.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 452110.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Tıbbi Sorumluluk Reddi

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.